EP1626717A4 - Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation - Google Patents

Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation

Info

Publication number
EP1626717A4
EP1626717A4 EP04751318A EP04751318A EP1626717A4 EP 1626717 A4 EP1626717 A4 EP 1626717A4 EP 04751318 A EP04751318 A EP 04751318A EP 04751318 A EP04751318 A EP 04751318A EP 1626717 A4 EP1626717 A4 EP 1626717A4
Authority
EP
European Patent Office
Prior art keywords
benzimidazoles
compounds
methods
compositions containing
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04751318A
Other languages
German (de)
English (en)
Other versions
EP1626717A2 (fr
Inventor
Emma R Parmee
Ronald M Kim
Rui Liang
Jiang Chang
Elizabeth Ashley Rouse
Kevin T Chapman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1626717A2 publication Critical patent/EP1626717A2/fr
Publication of EP1626717A4 publication Critical patent/EP1626717A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04751318A 2003-05-09 2004-05-05 Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation Withdrawn EP1626717A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46933203P 2003-05-09 2003-05-09
PCT/US2004/013874 WO2004100875A2 (fr) 2003-05-09 2004-05-05 Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation

Publications (2)

Publication Number Publication Date
EP1626717A2 EP1626717A2 (fr) 2006-02-22
EP1626717A4 true EP1626717A4 (fr) 2009-09-09

Family

ID=33452275

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04751318A Withdrawn EP1626717A4 (fr) 2003-05-09 2004-05-05 Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation

Country Status (6)

Country Link
EP (1) EP1626717A4 (fr)
JP (1) JP2006528687A (fr)
CN (1) CN1784226A (fr)
AU (1) AU2004238240A1 (fr)
CA (1) CA2524436A1 (fr)
WO (1) WO2004100875A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US7030113B2 (en) * 2003-10-02 2006-04-18 Schering Corporation Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
PT1756064E (pt) * 2004-06-04 2008-07-22 Merck & Co Inc Derivados de pirazole, composições contendo tais compostos e métodos de utilização
JP2008507528A (ja) 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
JP5281287B2 (ja) 2005-07-13 2013-09-04 Ｍｓｄ株式会社 ヘテロ環置換ベンズイミダゾール誘導体
AU2006276072A1 (en) 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
GEP20135844B (en) * 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
US8394969B2 (en) * 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
AR073486A1 (es) * 2009-02-06 2010-11-10 Takeda Pharmaceutical Compuesto heterociclico para diabetes
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
WO2011027849A1 (fr) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Composé hétérocyclique
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8927577B2 (en) * 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2019160940A1 (fr) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Antagonistes de récepteur de glucagon
WO2024158240A1 (fr) * 2023-01-25 2024-08-02 주식회사 자이메디 Nouveau composé utilisé en tant qu'inhibiteur de lysyl-arnt synthétase 1 et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (fr) * 1999-05-17 2000-11-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
EP1069124A1 (fr) * 1999-07-16 2001-01-17 Pfizer Inc. Dérivés de 2-benzimidazolamine comme agonistes du récepteur ORL1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705515A (en) * 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (fr) * 1999-05-17 2000-11-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
EP1069124A1 (fr) * 1999-07-16 2001-01-17 Pfizer Inc. Dérivés de 2-benzimidazolamine comme agonistes du récepteur ORL1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. M. KIM ET AL.: "Discovery of potent, orally active benzimidazole glucagon receptor antagonists", BIOORG. MED. CHEM. LETT., vol. 18, no. 13, 22 May 2008 (2008-05-22), pages 3701 - 3705, XP002537989 *

Also Published As

Publication number Publication date
JP2006528687A (ja) 2006-12-21
WO2004100875A3 (fr) 2005-03-17
CA2524436A1 (fr) 2004-11-25
CN1784226A (zh) 2006-06-07
WO2004100875A2 (fr) 2004-11-25
AU2004238240A1 (en) 2004-11-25
EP1626717A2 (fr) 2006-02-22

Similar Documents

Publication Publication Date Title
EP1626717A4 (fr) Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation
IL179754A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
IL173044A0 (en) Aryl and heteroaryl compounds, compositions, and methods of use
EP1699453A4 (fr) Guanidines cycliques, compositions contenant de tels composes et procedes d'utilisation
HK1083835A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HRP20040665B1 (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
GB0307891D0 (en) Chemical compounds,compositions and uses
HK1089436A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HK1090639A1 (en) Immunosuppressant compounds and compositions
HK1087929A1 (zh) 免疫抑制劑化合物和組合物
EP1644367A4 (fr) Compositions et composes immunosuppresseurs
GB0323845D0 (en) Chemical compounds,compositions and uses
IL172023A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HK1086485A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EP1858513A4 (fr) Cycloalcanes substitues par un diphenyle, compositions contenant de tels composes et methodes d utilisation
IL172027A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL190477A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EP1569915A4 (fr) Urees spirocycliques, compositions les contenant et procedes d'utilisation
AU2003256805A8 (en) Compounds compositions and methods
EP1651231A4 (fr) Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
EP1663255A4 (fr) Compositions de withanamide and withanolide et procede d'utilisation de celles-ci
EP1667999A4 (fr) Composes benzopyranone, compositions a partir de ces composes et technique de traitement utilisant ces compositions
EP1594849A4 (fr) Composes, compositions, et methodes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051209

Extension state: LT

Payment date: 20051209

A4 Supplementary search report drawn up and despatched

Effective date: 20090806

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091218